ChatzikonstantinouSGioulaGKimiskidisVKMcKennaJMavroudisIKazisD.The gut microbiome in drug-resistant epilepsy
In 2023 the FDA placed CJC-1295 in "Category 2" of its interim 503A bulks list, meaning it identified significant safety concerns and did not permit its use in traditional pharmacy compounding
Ermer et al., 2011), and the subjective effects are not enhanced by parenteral administration in contrast to D-amphetamine (Lile et al., 2011) thus reducing the risk of parenteral misuse of lisdexamfetamine compared with D-amphetamine
Autoimmune thyroid disease, its the number one autoimmune disease in the United States
[DOI] [PubMed] [Google Scholar] 145.Elia L., Contu R., Quintavalle M., Varrone F., Chimenti C., Russo M.A., Cimino V., De Marinis L., Frustaci A., Catalucci D., et al
In a small, prospective, randomized, double-blinded study, 34 people were given Dunaliella for 12 weeks